"He went through six operations and was placed on a clinical trial so he could try new treatments.”
A trial looking at photodynamic therapy (PDT) for brain tumours
We know that this is an especially worrying time for people with cancer and their family and friends. We have separate information about coronavirus and cancer. Please read that information alongside this page. We will update that information as guidance changes.
This trial was looking at whether photodynamic therapy alongside surgery is helpful for people who have just been diagnosed with a type of brain tumour called glioblastoma multiforme (GBM).
Photodynamic therapy (PDT) is a treatment that uses light. Trials had already taken place using PDT for brain tumours that had come back after treatment. This trial was looking PDT alongside surgery and radiotherapy as a first treatment.
People having photodynamic therapy in this trial had 2 drugs before they had surgery. The first of these drugs was called 5-ALA. It makes brain tumour cells glow red under ultra violet light. During surgery, the surgeon used an ultra violet light on a microscope to look for tumour cells that glow red and removed as many of these as possible.
The other drug was Photofrin. This drug is absorbed by cancer cells and is activated by light. A bright light was shone into the area where the brain tumour had been removed soon after surgery, and then once on each of the next 4 days. This activated the drug and helped to kill any cells that had been left behind.
Summary of results
The researchers found that it took longer for the brain tumours to start growing again in people who had photodynamic therapy.
The trial recruited 27 people who had just been diagnosed with a glioblastoma multiforme brain tumour.
They were put into 1 of 2 groups at random. Neither the person taking part, nor their doctor could decide which group they were in. This is called randomisation.
- 13 people had surgery and photodynamic therapy (PDT), followed by radiotherapy
- 14 people had surgery alone followed by radiotherapy (the
The researchers found that the average length of time people lived after treatment was longer in the PDT group.
They also looked at the time it took for the brain tumours to start growing again and found that it was
- Over 8 and a half months in the group of people who had PDT
- Less than 5 months in the control group
There was no difference between the groups in the length of time people stayed in hospital, or the complications they had after treatment. But by using a scale called the Karnofsky performance status, the researchers could see that for people in the PDT group, there was more of an improvement in how well they were and how many normal activities they were able to carry out 6 months after treatment.
This trial recruited a small number of people at 1 hospital. But as it took longer for the brain tumours to start growing again in people who had PDT, the researchers suggest this treatment should be looked at in a larger trial.
We have based this summary on information from the team who ran the trial. The information they sent us has been reviewed by independent specialists (
How to join a clinical trial
Prof Sam Eljamel
Ninewells Hospital and Medical School
The Barbara Stewart Cancer Trust